Article

Interim results favorable for QPI-1007

Quark Pharmaceuticals Inc. has announced favorable interim results from the first two cohorts of its open-label, first-in-human phase I clinical study of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy.

Fremont, CA-Quark Pharmaceuticals Inc. has announced favorable interim results from the first two cohorts of its open-label, first-in-human phase I clinical study of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION).

QPI-1007 exhibited no dose-limiting toxicities up to and including the highest dose of 6 mg enabled in this study, which is the highest dose of synthetic siRNA tested in the clinic following intravitreal administration.

After 3 months of follow up, patients treated in the study by a single dose of QPI-1007 exhibited no further loss of visual acuity, whereas vision loss was observed in previous studies in patients with non-treated NAION and similar initial disease severity. With the exception of one patient whose vision remained stable, all patients exhibited letter gains compared with baseline at screening, with some patients gaining three lines or more by 3 months after treatment.

The ongoing phase I open-label, dose-escalation study, which is being conducted at 22 sites in the United States and six in Israel, has enrolled a total of 38 patients in two strata. Stratum I was a dose-escalation safety study in patients who are legally blind secondary to chronic optic nerve atrophy or retinal degeneration and is fully enrolled. Stratum II was designed to evaluate safety further and to assess for potential biological activity of QPI-1007 in patients with recent-onset NAION by monitoring changes in visual function following drug administration.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.